A. Ercaliskan And A. E. Eskazan, "The Impact of BCR-ABL1 Transcript Type on Tyrosine Kinase Inhibitor Responses and Outcomes in Patients with Chronic Myeloid Leukemia," CANCER , vol.124, no.19, pp.3806-3818, 2018
Ercaliskan, A. And Eskazan, A. E. 2018. The Impact of BCR-ABL1 Transcript Type on Tyrosine Kinase Inhibitor Responses and Outcomes in Patients with Chronic Myeloid Leukemia. CANCER , vol.124, no.19 , 3806-3818.
Ercaliskan, A., & Eskazan, A. E., (2018). The Impact of BCR-ABL1 Transcript Type on Tyrosine Kinase Inhibitor Responses and Outcomes in Patients with Chronic Myeloid Leukemia. CANCER , vol.124, no.19, 3806-3818.
Ercaliskan, Abdulkadir, And A. Emre Eskazan. "The Impact of BCR-ABL1 Transcript Type on Tyrosine Kinase Inhibitor Responses and Outcomes in Patients with Chronic Myeloid Leukemia," CANCER , vol.124, no.19, 3806-3818, 2018
Ercaliskan, Abdulkadir And Eskazan, A. E. . "The Impact of BCR-ABL1 Transcript Type on Tyrosine Kinase Inhibitor Responses and Outcomes in Patients with Chronic Myeloid Leukemia." CANCER , vol.124, no.19, pp.3806-3818, 2018
Ercaliskan, A. And Eskazan, A. E. (2018) . "The Impact of BCR-ABL1 Transcript Type on Tyrosine Kinase Inhibitor Responses and Outcomes in Patients with Chronic Myeloid Leukemia." CANCER , vol.124, no.19, pp.3806-3818.
@article{article, author={Abdulkadir Ercaliskan And author={A. Emre Eskazan}, title={The Impact of BCR-ABL1 Transcript Type on Tyrosine Kinase Inhibitor Responses and Outcomes in Patients with Chronic Myeloid Leukemia}, journal={CANCER}, year=2018, pages={3806-3818} }